

<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)				Attorney Docket No. <b>067802-5012-US01</b>		Application No. <b>10/500,804</b>	
<b>PTO Form 1449</b>				Applicants: <b>Christophe Bonny</b>			
				Filing Date: <b>January 7, 2005</b>		Group Art Unit: <b>1649</b>	
<b>U.S. PATENT DOCUMENTS</b>							
<b>Initial</b>	<b>Document No.</b>	<b>Date</b>	<b>Name</b>	<b>Class</b>	<b>Sub-Class</b>	<b>Filing Date</b>	
A01	US 4,631,211	December 23, 1986	Houghten				
A02	US 6,348,185	February 19, 2002	Piwnica-Worms				
A03	US 6,653,443	November 25, 2003	Zhang et al.				
<b>FOREIGN PATENT DOCUMENTS</b>							
	<b>Document No.</b>	<b>Date</b>	<b>Country</b>	<b>Class</b>	<b>Sub-Class</b>	<b>Translation</b>	
B01	WO 94/04686	March 3, 1994	WIPO				
B02	WO 98/47913	October 29, 1998	WIPO				
B03	WO 98/49188	November 5, 1998	WIPO				
B04	WO 99/50282	October 7, 1999	WIPO				
B05	WO 99/58561	November 18, 1999	WIPO				
B06	WO 01/27268	April 19, 2001	WIPO				
B07	WO 02/81504	October 17, 2002	WIPO				
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)</b>							
C01	Abaza et al. "Effects of amino acid substitutions outside an antigenic site on protein binding to monoclonal antibodies of predetermined specificity obtained by peptide immunization: demonstration with region 94-100 (antigenic site 3) of myoglobin" J. Protein Chem. 11(5), pp 433-444 (1992)						
C02	Agrawal et al. "Promiscuous binding nature of SH3 domains to their target proteins", Protein Pept. Lett., 9(3):185-193 (2002)						
C03	Bonny et al. "Cell-permeable peptide inhibitors of JNK: novel blockers of beta-cell death", Diabetes, 50(1):77-82 (2001)						
C04	Borsello et al. "A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia", Nat Med. 9(9), pp 1180-1186 (2003)						
C05	Creighton, T. Encyclopedia of Molecular Biology, John Wiley and Sons, Inc. New York, pp 2027-2033 (1999)						
C06	Diabetes, A Journal of the American Diabetes Association. Abstract Book. 61st Scientific Sessions, Pennsylvania Convention Center, PA 50 (Suppl 2), June, 2001.						
C07	Fawell et al. "Tat-mediated delivery of heterologous proteins into cells" Proc. Natl. Acad. Sci. USA. 91(2), pp 664-668 (1994)						
C08	GenBank Database Accession Number PH0878, May 1997.						
C09	Huq et al. "Specific recognition of HIV-1 TAR RNA by a D-Tat peptide", Nat Struct Biol. 4(11), pp 881-882 (1997)						
C10	Houghten, "General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids", Proc. Natl. Acad. Sci. USA, 82(15):5131-5135 (1985).						
C11	International Search Report for PCT/IB03/00332, mailing date: July 19, 2004						
C12	Kishan et al. "SH3-like fold proteins are structurally conserved and functionally divergent", Curr. Protein Pept. Sci., 6(2):143-150 (2005)						
C13	Li, S. "Specificity and versatility of SH3 and other proline-recognition domains: structural basis and implications for cellular signal transduction", Biochem. J., 390(Pt 3):641-653 (2005)						
C14	Mayer et al.: "SH3 domains: complexity in moderation", J. Cell Science, vol. 114(7), pp 1253-1263. 1997						
C15	Moulin et al. "Islet-brain (IB)/JNK-interacting proteins (JIPs): future targets for the treatment of neurodegenerative diseases?", Curr. Neurovasc. Res., 1(2):111-127 (2004)						
C16	Rickles et al. "Phage display selection of ligand residues important for Src homology 3 domain binding specificity", 92(24): 10909-10913 (1995)						
Examiner /Stephen Gucker/			Date Considered 07/29/2009				
<b>Examiner:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SG/

